Terms: = Thyroid cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Prognosis
441 results:
1. Proteostatic reactivation of the developmental transcription factor TBX3 drives braf/MAPK-mediated tumorigenesis.
Zhang Z; Wu Y; Fu J; Yu X; Su Y; Jia S; Cheng H; Shen Y; He X; Ren K; Zheng X; Guan H; Rao F; Zhao L
Nat Commun; 2024 May; 15(1):4108. PubMed ID: 38750011
[TBL] [Abstract] [Full Text] [Related]
2. [The clinicopathological features of adult thyroid tumors with DICER1 mutation].
Tang J; Huang JJ; Luo YL; Zhang LK; Wang QQ; Chen J; Liu ZY
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1623-1627. PubMed ID: 38742350
[TBL] [Abstract] [Full Text] [Related]
3. Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma.
Huang Y; Lin P; Liao J; Liang F; Han P; Fu S; Jiang Y; Yang Z; Tan N; Huang J; Chen R; Ouyang N; Huang X
BMC Endocr Disord; 2024 May; 24(1):68. PubMed ID: 38734621
[TBL] [Abstract] [Full Text] [Related]
4. Columnar Cell thyroid Carcinoma: A Heterogeneous Entity Demonstrating Overlap Between Papillary thyroid Carcinoma and Follicular Neoplasms.
Higgins KE; Sadow PM; Johnson DN; Wang P; Wanjari P; Cipriani NA
Head Neck Pathol; 2024 May; 18(1):39. PubMed ID: 38727854
[TBL] [Abstract] [Full Text] [Related]
5. Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.
Syed AR; Gorana A; Nohr E; Yuan XK; Amin MASc P; Ghaznavi S; Lamb D; McIntyre J; Eszlinger M; Paschke R
Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642578
[TBL] [Abstract] [Full Text] [Related]
6. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
7. Genetic alterations and allele frequency of braf V600E and TERT mutation in papillary thyroid carcinoma with intermediate-to-high recurrence risk: a retrospective study.
Huang J; Wang J; Xv J; Wang J; Wang G; Zhao Y
Clin Exp Med; 2024 Apr; 24(1):76. PubMed ID: 38607456
[TBL] [Abstract] [Full Text] [Related]
8. Combined braf and PIM1 inhibitory therapy for papillary thyroid carcinoma based on brafV600E regulation of PIM1: Synergistic effect and metabolic mechanisms.
Xu Q; Wang J; Mao Y; Xuan Z; Yang K; Tang X; Zhu X
Neoplasia; 2024 Jun; 52():100996. PubMed ID: 38593698
[TBL] [Abstract] [Full Text] [Related]
9. braf
Zhao H; Liu CH; Lu Y; Liu SZ; Yeerkenbieke P; Cao Y; Xia Y; Gao LY; Liu YW; Liu ZW; Chen SG; Liang ZY; Li XY
Oral Oncol; 2024 May; 152():106755. PubMed ID: 38547780
[TBL] [Abstract] [Full Text] [Related]
10. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated thyroid Carcinomas.
Matos ML; Pinto M; Alves M; Canberk S; Gonçalves A; Bugalho MJ; Papoila AL; Soares P
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540448
[TBL] [Abstract] [Full Text] [Related]
11. Papillary thyroid carcinoma tall cell subtype (PTC-TC) and high-grade differentiated thyroid carcinoma tall cell phenotype (HGDTC-TC) have different clinical behaviour: a retrospective study of 1456 patients.
Ghossein R; Katabi N; Dogan S; Shaha AR; Tuttle RM; Fagin JA; Ganly I; Xu B
Histopathology; 2024 Jun; 84(7):1130-1138. PubMed ID: 38528726
[TBL] [Abstract] [Full Text] [Related]
12. Advances in targeted therapy and biomarker research in thyroid cancer.
Guo M; Sun Y; Wei Y; Xu J; Zhang C
Front Endocrinol (Lausanne); 2024; 15():1372553. PubMed ID: 38501105
[TBL] [Abstract] [Full Text] [Related]
13. Progress in long non-coding RNAs as prognostic factors of papillary thyroid carcinoma.
Zhu HN; Song DL; Zhang SN; Zheng ZJ; Chen XY; Jin X
Pathol Res Pract; 2024 Apr; 256():155230. PubMed ID: 38461693
[TBL] [Abstract] [Full Text] [Related]
14. Correlation between genetic alterations and clinicopathological features of papillary thyroid carcinomas.
Shang S; Yang H; Chen M; Wu J; Shi X; Li X; Feng N; Zheng Z; Liu H; Zhang Y
J Int Med Res; 2024 Mar; 52(3):3000605241233166. PubMed ID: 38456650
[TBL] [Abstract] [Full Text] [Related]
15. CD73 mitigates ZEB1 expression in papillary thyroid carcinoma.
Vedovatto S; Oliveira FD; Pereira LC; Scheffel TB; Beckenkamp LR; Bertoni APS; Wink MR; Lenz G
Cell Commun Signal; 2024 Feb; 22(1):145. PubMed ID: 38388432
[TBL] [Abstract] [Full Text] [Related]
16. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
Yu J; Liu Z; Su Y; Peng X; Xie Y
Clin Endocrinol (Oxf); 2024 Apr; 100(4):379-388. PubMed ID: 38351437
[TBL] [Abstract] [Full Text] [Related]
17. braf V600E Mutation Lacks Association with Poorer Clinical prognosis in Papillary thyroid Carcinoma.
Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
[TBL] [Abstract] [Full Text] [Related]
18. Clinical and molecular features of progressive papillary thyroid microcarcinoma.
Wang Z; Ji X; Zhang H; Sun W
Int J Surg; 2024 Apr; 110(4):2313-2322. PubMed ID: 38241301
[TBL] [Abstract] [Full Text] [Related]
19. Expression of
Soboska K; Kusiński M; Pawelczyk K; Migdalska-Sęk M; Brzeziańska-Lasota E; Czarnecka-Chrebelska KH
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203733
[TBL] [Abstract] [Full Text] [Related]
20. Artificial Intelligence Detected the Relationship Between Nuclear Morphological Features and Molecular Abnormalities of Papillary thyroid Carcinoma.
Nishikawa T; Matsuzaki I; Takahashi A; Ryuta I; Musangile FY; Sagan K; Nishikawa M; Mikasa Y; Takahashi Y; Kojima F; Murata SI
Endocr Pathol; 2024 Mar; 35(1):40-50. PubMed ID: 38165630
[TBL] [Abstract] [Full Text] [Related]
[Next]